AstraZeneca widens disclosure policy

Share this article:
AstraZeneca's David Nicoli
AstraZeneca's David Nicoli
As other drugmakers come under fire for being slow to release info on clinical trials and monetary donations, AstraZeneca plans to widen its disclosure policy at its US website in an effort to create greater transparency into how it conducts its business.

Under the new plans, information related to political and non profit contributions, medical education grants and post-marketing study commitments will be made available for the first time on

“We believe in providing information to the public about our company, our products and how we do business as part of our commitment to improving patient health and corporate responsibility,” said David Nicoli, VP of corporate affairs. “This important information will help the public better understand significant aspects of our business.”

AstraZeneca's info sharing plan will be rolled out in three waves during 2008. First, the company plans to expand present info on policy positions, clinical trials and compliance program details. 

In the second-quarter of 2008, the drugmaker will begin posting political contribution information on its US site. By fall 2008, more info on medical education grants, third party contributions and post-marketing study commitments will be available.

“We believe that medical education is a very important part of improving patient care,” AstraZeneca spokesman Tony Jewell said. “By providing healthcare professionals with the most current information on diseases and treatment options is the best way for doctors and patients to communicate about our products.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...